Loading clinical trials...
Loading clinical trials...
Phase II Study to Evaluate the Efficacy of Recombinant Interferon-Alpha in the Treatment of Recurrent Unresectable Meningiomas and Malignant Meningiomas
Conditions
Interventions
Recombinant Interferon Alfa (INF alpha)
Locations
1
United States
University of Texas - MD Anderson Cancer Center
Houston, Texas, United States
Start Date
January 1, 1997
Primary Completion Date
March 1, 2003
Completion Date
March 1, 2003
Last Updated
December 22, 2023
NCT00602667
NCT00978458
NCT00683319
NCT07416188
NCT00897286
NCT06742593
Lead Sponsor
M.D. Anderson Cancer Center
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions